Valeant Director Ingram Says Pearson Has Board's Full Support

Updated on
  • Company was accused of fraud by short seller Citron Research
  • Drugmaker's stocks, bonds have plunged since report published

Digging Into Valeant: Are We Seeing 'Phantom' Revenue?

Robert Ingram, a director of Valeant Pharmaceuticals International Inc., said Chief Executive Officer Michael Pearson has “unanimous and strong support” from the board.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.